SIRT3 and Hepatic fibrosis: In line with the previous studies, this study found that WFA is a potent inducer of SIRT3 and increased the SIRT3 expression both in a PDGF-BB-induced in vitro fibrotic model and a CCl4-induced in vivo liver fibrosis model, and SIRT3 siRNA or SIRT3 knockout attenuated the antifibrogenic effect of WFA mainly by the inhibition of oxidative stress, thus further suggesting that SIRT3 is a promising therapeutic target for the treatment of liver-related diseases.